卡尔-T细胞疗法的心脏毒性作用:更新的系统性审查和元分析
Roberto A S V Mazetto1, Sarah O N Monteiro2, Elísio Bulhões3
1Medicine Department, Amazonas State University, Manaus, Brazil.
化学抗原受体T细胞 (CAR-T) 治疗可以在近20%的血液恶性瘤患者中引起心血管事件. 以前患有心脏病的患者面临更高的风险,需要在CAR-T治疗期间仔细监测心脏.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法在血液恶性瘤中显示出前景.
- 治疗CAR-T的潜在心脏毒性需要进行彻底的调查.
结论:
- 对于接受CAR-T治疗的患者来说,警的心血管监测至关重要.
- 这种监测提高了安全性和治疗疗效.
- 积极管理心脏风险对于成功的CAR-T治疗结果至关重要.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
08:09Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
Published on: March 14, 2025
相关概念视频
Myocarditis III: Medical Management
Pericarditis III: Medical Management
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)